AORT (Artivion) ROCE %: 2.90% (As of Mar. 2026)

What is Artivion ROCE %?

Artivion AORT +2.86% 81 ROCE % is 2.90% as of Mar. 2026. GuruFocus rates AORT with a GF Score™ of 81/100 and a GF Value™ of $28.37 (Modestly Undervalued). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Artivion's annualized ROCE % for the quarter that ended in Mar. 2026 was 2.90%.

Artivion (NYSE:AORT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Artivion ROCE % Related Terms

Artivion ROCE % Historical Data

* Premium members only.

The historical data trend for Artivion's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Artivion ROCE % Chart

Artivion Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

0.28

0.44

0.51

3.67

5.49

Artivion Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															2.94	5.69	6.83	6.21	2.90

81GF Score

Artivion Inc AORT

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Artivion ROCE % Calculation

Artivion's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	41.362	/	( ( (789.101 - 66.823)	+	(884.796 - 101.556) )	/ 2 )
	=	41.362	/	( (722.278	+	783.24)	/ 2 )
	=	41.362	/	752.759
	=	5.49 %

Artivion's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	22.824	/	( ( (884.796 - 101.556)	+	(883.157 - 92.7) )	/ 2 )
	=	22.824	/	( ( 783.24	+	790.457 )	/ 2 )
	=	22.824	/	786.8485
	=	2.90 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 2.90% mean?

Artivion (AORT) has a ROCE % of 2.90% as of Mar. 2026.

Is Artivion's ROCE % too high?

Artivion's current ROCE % is 2.90%. The Medical Devices & Instruments industry median ROCE % is 2.23. Artivion's value of 2.90% is 30% above this industry median. Overall, Artivion has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Artivion's ROCE % compare to CNMD and AVNS?

Artivion's ROCE % of 2.90% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. Artivion's value of 2.90% is 30% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Artivion's current ROCE % of 2.90% is 30% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Artivion's current ROCE % is 2.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Artivion stock overvalued right now?

Based on GuruFocus' analysis, Artivion (AORT) is currently considered Modestly Undervalued. The stock's GF Value™ is $28.37, compared to a current price of $22.66 — trading 20.1% below its estimated fair value. The current ROCE % is 2.90% and 30% above the Medical Devices & Instruments industry median of 2.23. Artivion's overall GF Score™ is 81/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Artivion (AORT), the current ROCE % is 2.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Artivion (AORT) Overvalued in 2026?

Based on GuruFocus' analysis, Artivion stock appears to be undervalued. The current stock price of $22.66 is trading 20.1% below its estimated GF Value™ of $28.37. GuruFocus considers Artivion to be Modestly Undervalued.

Key valuation signals for AORT:

ROCE %: 2.90%
GF Value™: $28.37 vs. price of $22.66 (20.1% below fair value)
GF Score™: 81/100 with 5 warning signs
Industry Position: 30% above the Medical Devices & Instruments median

No single metric tells the full story. See the AORT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Artivion Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies CNMD AVNS IRMD TNDM ATEC BFLY INSP IART QDEL INMD ABT SYK MDT BSX EW XTER:SHL DXCM GEHC SZSE:300760 XAMS:PHIA

Other Exchanges CYL:Germany

Address 1655 Roberts Boulevard North West, Kennesaw, GA, USA, 30144

Website https://www.artivion.com

Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.

81GF Score

Get the complete analysis for AORT

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.66

Price

$28.37

GF Value

View AORT Analysis

See ROCE % data for all stocks →